| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Breast cancer
Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study
Kuikui Jiang, Ruoxi Hong, Wen Xia, Qianyi Lu, Liang Li, Jianhao Huang, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Fei Xu, Shusen Wang
Cancer Res Treat. 2024;56(2):513-521.   Published online October 12, 2023    DOI: https://doi.org/10.4143/crt.2023.786
                        
Lung and Thoracic cancer
Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Miso Kim, Soyeon Kim, Jeemin Yim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo
Cancer Res Treat. 2023;55(4):1134-1143.   Published online May 23, 2023    DOI: https://doi.org/10.4143/crt.2023.311
                        Supplementary      
Hematologic malignancy
Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia
Jun-Xia Wang, Miao-Miao Yang, Li-Peng Liu, Hui-Min Zhang, Meng-Chuan Wang, Yu-Wen Chen, Xiao-Ying Zang, Fang Hu
Cancer Res Treat. 2023;55(3):1023-1030.   Published online February 6, 2023    DOI: https://doi.org/10.4143/crt.2022.1618
                        
Lung and Thoracic cancer
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Cancer Res Treat. 2023;55(3):841-850.   Published online February 13, 2023    DOI: https://doi.org/10.4143/crt.2022.1438
                        Supplementary         Web of Science 2  Crossref 5
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Res Treat. 2022;54(2):434-444.   Published online August 2, 2021    DOI: https://doi.org/10.4143/crt.2021.671
                           Web of Science 8  Crossref 10
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2020;52(4):1288-1290.   Published online June 22, 2020    DOI: https://doi.org/10.4143/crt.2020.278
                           Web of Science 17  Crossref 8
Breast cancer
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
Ying Lin, Mingxi Lin, Jian Zhang, Biyun Wang, Zhonghua Tao, Yiqun Du, Sheng Zhang, Jun Cao, Leiping Wang, Xichun Hu
Cancer Res Treat. 2020;52(4):1059-1066.   Published online April 24, 2020    DOI: https://doi.org/10.4143/crt.2019.633
                        Supplementary         Web of Science 31  Crossref 16
RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
Tian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang, Hang-Ping Yao
Cancer Res Treat. 2020;52(3):973-986.   Published online April 22, 2020    DOI: https://doi.org/10.4143/crt.2019.726
                        Supplementary         Web of Science 14  Crossref 14
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee
Cancer Res Treat. 2020;52(1):284-291.   Published online July 23, 2019    DOI: https://doi.org/10.4143/crt.2019.200
                           Web of Science 5  Crossref 4
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Seulki Kim, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Yong-Oon Ahn, Bhumsuk Keam, Dae Seog Heo
Cancer Res Treat. 2019;51(3):951-962.   Published online October 10, 2018    DOI: https://doi.org/10.4143/crt.2018.052
                        Supplementary         Web of Science 42  Crossref 41
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):623-631.   Published online July 23, 2018    DOI: https://doi.org/10.4143/crt.2018.151
                        Supplementary         Web of Science 43  Crossref 36
Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
In Kyoung Hwang, Seung Sook Paik, Seung Hyeun Lee
Cancer Res Treat. 2019;51(1):158-168.   Published online April 2, 2018    DOI: https://doi.org/10.4143/crt.2018.084
                        Supplementary         Web of Science 15  Crossref 13
EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
Cancer Res Treat. 2018;50(3):908-916.   Published online September 19, 2017    DOI: https://doi.org/10.4143/crt.2017.378
                           Web of Science 32  Crossref 25
Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model
Pawel Chrom, Rafal Stec, Lubomir Bodnar, Cezary Szczylik
Cancer Res Treat. 2018;50(1):103-110.   Published online March 3, 2017    DOI: https://doi.org/10.4143/crt.2017.033
                        Supplementary         Web of Science 27  Crossref 30
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han
Cancer Res Treat. 2017;49(4):1001-1011.   Published online January 13, 2017    DOI: https://doi.org/10.4143/crt.2016.546
                           Web of Science 42  Crossref 34
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee
Cancer Res Treat. 2017;49(4):981-989.   Published online January 6, 2017    DOI: https://doi.org/10.4143/crt.2016.522
                        Supplementary         Web of Science 13  Crossref 13
Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang
Cancer Res Treat. 2016;48(3):1110-1119.   Published online January 6, 2016    DOI: https://doi.org/10.4143/crt.2015.289
                           Web of Science 7  Crossref 7
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo
Keun-Yong Eom, Bong Jun Cho, Eun Jung Choi, Jin-Ho Kim, Eui Kyu Chie, Hong-Gyun Wu, Il Han Kim, Sun Ha Paek, Jae-Sung Kim, In Ah Kim
Cancer Res Treat. 2016;48(2):687-697.   Published online June 4, 2015    DOI: https://doi.org/10.4143/crt.2014.320
                           Web of Science 25  Crossref 22
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea
Jaemin Jo, Jung Ho Kim, Ji Young Kim, Changlim Hyun, Jiyoung Rhee, Jungmi Kwon, Sanghoon Han, Wookun Kim
Cancer Res Treat. 2016;48(1):393-397.   Published online February 17, 2015    DOI: https://doi.org/10.4143/crt.2014.209
                        
A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib
Meral Gunaldi, Ismail Oguz Kara, Berna Bozkurt Duman, Cigdem Usul Afsar, Melek Ergin, Arbil Avci
Cancer Res Treat. 2014;46(4):411-414.   Published online July 18, 2014    DOI: https://doi.org/10.4143/crt.2013.093
                           Web of Science 3  Crossref 2
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
Cancer Res Treat. 2014;46(4):323-330.   Published online July 14, 2014    DOI: https://doi.org/10.4143/crt.2013.120
                           Web of Science 23  Crossref 19
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim
Cancer Res Treat. 2013;45(2):79-85.   Published online June 30, 2013    DOI: https://doi.org/10.4143/crt.2013.45.2.79
                           Crossref 14
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
D. Nathan Kim, Taek-Keun Nam, Kevin S. Choe, Hak Choy
Cancer Res Treat. 2012;44(2):74-84.   Published online June 30, 2012    DOI: https://doi.org/10.4143/crt.2012.44.2.74
                           Crossref 5
Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Keun-Wook Lee, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn
Received January 2, 2024   Accepted April 14, 2024   Published online April 15, 2024
DOI: https://doi.org/10.4143/crt.2024.008    
[Accepted]
      
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Journal Impact Factor 4.1
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI